Clinical Trials Browser

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02755597 2023-08-22

Bellini

Phase 3 Completed

291 enrolled 24 charts

Plasma cell

Multiple Myeloma

NCT01850524 2023-07-21

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

705 enrolled 30 charts

Plasma cell

Multiple Myeloma

NCT04649060 2023-06-08

LIGHTHOUSE

Phase 3 Terminated

54 enrolled 21 charts

Plasma cell

Multiple Myeloma

NCT01734928 2023-06-06

OPTIMISMM

Phase 3 Completed

559 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT02516696 2023-06-05

BiRd vs Rd

Phase 3 Terminated

12 enrolled 19 charts

Plasma cell

Multiple Myeloma

NCT02726581 2023-03-27

CheckMate 602

Phase 3 Completed

170 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT01564537 2023-03-10

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 3 Completed

722 enrolled 29 charts

Plasma cell

Multiple Myeloma

NCT02609828 2023-02-16

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Phase 3 Completed

156 enrolled 31 charts

Plasma cell

Cancer Pain, Multiple Myeloma

NCT01568866 2022-11-14

ENDEAVOR

Phase 3 Completed

929 enrolled 21 charts

Plasma cell

Multiple Myeloma

NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Phase 3 Completed

1,718 enrolled 22 charts

Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT00330759 2022-11-07

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Phase 3 Completed

1,779 enrolled 14 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Spinal Cord Compression

NCT01335399 2022-09-30

ELOQUENT - 1

Phase 3 Completed

748 enrolled 15 charts

Plasma cell

Multiple Myeloma

NCT02412878 2022-09-23

ARROW

Phase 3 Completed

478 enrolled 17 charts

Plasma cell

Multiple Myeloma

Clinical Trials

AURIGA

CARTITUDE-4

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

DREAMM-3

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Perseus

IKEMA

DFCI 10-106

GENESIS

EMN14

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

(Mel/MelVel)

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

DREAMM 8

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

CANDOR

DREAMM 7

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

DREAMM 7

Cassiopeia

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

DREAMM 8

VCAT

ICARIA-MM

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

DREAMM 7

BOSTON

ARROW2

OCEAN

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Bellini

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

LIGHTHOUSE

OPTIMISMM

BiRd vs Rd

CheckMate 602

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

ENDEAVOR

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

ELOQUENT - 1

ARROW